For decades, the battle against aggressive tumours in youth has relied on harsh tools such as toxic chemotherapy and high-dose radiation. Synovial sarcoma, a rare but serious soft tissue cancer that affects young people's arms and legs, may only be treated surgically if detected early. When the disease spreads to the lungs or returns after therapy, the alternatives are limited, severe, and frequently ineffective. 

Researchers at Osaka Metropolitan University believe they have discovered the tumor's "Achilles' heel"—not by poisoning it but by starving it. 

Synovial sarcoma primarily affects adolescents and young adults. It grows quickly and spreads silently. When it metastasises, traditional chemotherapy can have serious side effects such as liver strain, weight loss, and fatigue, while not always curing the cancer. The critical question for scientists has been clear: is there a better approach to attack it? 

Instead of asking what medicine could eliminate the tumour, graduate researchers Tran Duc Thanh and Dr Naoki Takada researched what this malignancy feeds on to survive. 

Cancer cells, like fast-growing parasites, consume significantly more nutrients than healthy cells. One of their preferred fuels is glutamine, a naturally occurring amino acid present in the body and in protein-rich diets. Amino acids are the building blocks of proteins, which organisms require for growth and repair. However, cancer cells use glutamine in exceptionally large amounts to fuel their rapid development. 

The Japanese researchers discovered that synovial sarcoma cells produce enormous amounts of a transporter protein known as ASCT2. Simply put, ASCT2 operates as a little "mouth" on the cancer cell's surface, drawing glutamine within. Compared to other sarcomas, synovial sarcoma appears to be particularly dependent on this nutritional system. 

The researchers tested a chemical called V9302 to see if restricting this supply channel would weaken the cancer. Instead of directly treating the malignancy, V9302 inhibits the ASCT2 transporter, essentially closing the cell's mouth and cutting off glutamine uptake. 

Laboratory investigations on synovial sarcoma cells revealed that when glutamine was depleted or treated with V9302, the cancer cells stopped proliferating and initiated apoptosis, a type of programmed self-destruction. Apoptosis is the body's natural process of eliminating damaged or hazardous cells. 

Importantly, normal healthy cells were significantly less affected. 

The team then switched to animal models. Mice injected with synovial sarcoma cells and treated with V9302 had drastically reduced tumour growth. Crucially, the treated mice showed no severe side effects, such as weight loss or liver and kidney damage. 

"This study found that synovial sarcoma is heavily reliant on glutamine and that inhibiting ASCT2 shows potential. This will result in the creation of novel treatments that not only target cancer cells directly with anticancer medications but also weaken cancer by cutting off its food supply," Tran Duc Thanh said. 

Dr Takada noted that the findings are still in the early stages. "However, since this research primarily involves experiments on cells and mice, we still need to investigate whether the same effect occurs in other cases of synovial sarcoma, whether it is safe for human use, and what the optimal application method is," the doctor said. 

The study, published in Cancers, represents a broader movement in oncology toward targeting cancer metabolism, which refers to the internal energy systems that tumours use. Instead of bombarding the body with hazardous medications, future treatments could specifically weaken cancer by cutting off its nutrient supply. 

For young patients facing a life-threatening diagnosis, this shift could result in treatments that are not only more successful but also significantly more compassionate.